AstraZeneca Collaborates with Junshi to Commercialize Toripalimab in China

 AstraZeneca Collaborates with Junshi to Commercialize Toripalimab in China

AstraZeneca Collaborates with Junshi to Commercialize Toripalimab in China

Shots:

  • AstraZeneca to get exclusive promotion rights for toripalimab in mainland China for the urothelial carcinoma indications and all indications in non-core areas
  • Junshi will continue responsible for the promotion of other approved indications and to be approved excluding urothelial carcinoma in core areas
  • The companies will continue to explore overseas business collaborations including emerging markets and actively explore the possibility of expanding the future collaborations

Click here ­to­ read full press release/ article | Ref: GlobeNewswire | Image: Fierce Pharma

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post